PBS funding rules blamed for underuse of Botox in post-stroke spasticity

Australia is lagging behind the rest of the world when it comes to the use of botulinim toxin for post-stroke spasticity, new figures suggest. The Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee (PBAC) has noted that the use of botulinum toxin is low in the context of post-stroke spasticity. It found 742 ...

Already a member?

Login to keep reading.

© 2021 the limbic